Friday, 25 September 2026European Markets

BELIEVE Stock Bullish Momentum With A 25% Jump In The Last 10 Sessions

Loading stream...

(vianews) - shares of believe (cac 40: blv.pa) rose by a staggering 25.98% in 10 sessions from €9.7 to €12.22 at 20:52 est on friday, after five sequential sessions in a row of gains. cac 40 is rising 0.45% to €7,414.85, following the last session's upward trend.

believe's last close was €12.24, 1.16% above its 52-week high of €12.10.

about believe

believe s.a. provides music distribution and marketing services for artists and labels worldwide. the company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. it also provides trade marketing, video, sync, and additional services; and technology and analytics for clients to manage and promote their catalog. believe s.a. was incorporated in 2005 and is headquartered in paris, france.

earnings per share

as for profitability, believe has a trailing twelve months eps of €-0.2.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -6.32%.

volume

today's last reported volume for believe is 26457 which is 30.23% below its average volume of 19475.

more news about believe (blv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com